Today: 9 June 2026
Joby Aviation stock (JOBY) in focus after Ohio factory deal as CPI looms
11 January 2026
2 mins read

Joby Aviation stock (JOBY) in focus after Ohio factory deal as CPI looms

New York, Jan 10, 2026, 18:25 EST — The market has closed.

  • Joby shares closed Friday roughly 0.9% higher at $15.39, following a volatile trading session.
  • The air-taxi manufacturer revealed a deal to acquire a manufacturing facility in Ohio as it pushes forward with scaling up production.
  • Traders are now focused on Tuesday’s U.S. inflation figures and Joby’s upcoming earnings report as key near-term indicators.

Shares of Joby Aviation climbed roughly 0.9% Friday, closing at $15.39 on volume near 34 million. The stock fluctuated between $14.97 and $16.01 throughout the session.

This move is significant because investors have fixated on one key issue in this segment: whether electric air-taxi companies can scale production without derailing schedules or inflating costs. Joby and its rivals are still navigating certification and manufacturing hurdles, and their stock prices hinge on hitting those targets.

Joby is advancing its electric vertical takeoff and landing aircraft, or eVTOLs—planes that lift off like helicopters before switching to winged flight. This week, it announced a deal to buy a second manufacturing facility near Dayton, Ohio, covering over 700,000 square feet. The move supports a plan to boost production to four aircraft per month by 2027. CEO JoeBen Bevirt said, “This site will not only support our near-term plan to double production, it can also serve as a base for significant future growth.” SEC

A regulatory filing clarified the details. A Joby subsidiary has agreed to purchase the property for $61.5 million and will deposit $1 million in escrow. The closing depends on due diligence on the title and financing linked to the seller, the filing revealed.

The sector drew notice beyond CES buzz. Archer Aviation announced Thursday it will tap Nvidia’s IGX Thor platform to build aviation AI tech, underscoring how eVTOL firms are selling investors on entire “systems” approaches, not just planes. Archer Aviation

Macro factors could still drive the next big shift. The U.S. Consumer Price Index for December 2025 hits Tuesday, Jan. 13 at 8:30 a.m. ET. This report has the potential to reshape rate forecasts and shake up appetite for high-growth stocks.

The Federal Reserve will hold its next policy meeting on Jan. 27-28, with interest rate moves taking a backseat as markets adjust post-holidays.

JOBY has been bouncing around the $15 mark, with traders seeing it as a key short-term level. The $16 area is now emerging as the next obstacle if momentum picks up again.

Investors will zero in on the straightforward details: how fast Joby can convert new floor space into real production, and the impact on expenses. Any news on capital requirements, equipment schedules, or hiring—no matter how minor—could sway a stock that still hinges on “next step” developments.

The downside risk is all too familiar. Delays in certification or hiccups in scaling production due to supply-chain or cash issues could quickly undermine the 2027 output target, sending the stock lower in short order.

Joby hasn’t announced when it plans to release its next earnings, but MarketBeat projects the report will drop on Wednesday, Feb. 25, following previous patterns. Investors will focus on any updates about cash burn and expect clarity on how the Ohio expansion aligns with the production schedule.

Stock Market Today

  • Factorial Energy Shares Surge After Nasdaq Ticker Change from Cartesian Growth
    June 9, 2026, 9:18 AM EDT. Factorial Energy (ticker FAC) began trading on Nasdaq after merging with Cartesian Growth Corporation III (CGCT), marking the SPAC's transition from a shell company to an operating battery tech firm. Shares surged 16% to $13.80 on June 8, with premarket quotes near $20.70 the next day. The merger valued Factorial at approximately $1.3 billion and raised over $100 million to support commercializing solid-state batteries, which offer improved range and safety over traditional lithium-ion cells. CEO Siyu Huang emphasized the listing will accelerate the company's development. Factorial focuses on validation milestones, with partnerships including Mercedes-Benz and Stellantis. The move positions Factorial alongside public battery tech firms like QuantumScape and Solid Power, amid investor reshuffling following the transaction.

Latest articles

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
AmpliTech’s 5G Radio Test Moves AMPG Shares

AmpliTech’s 5G Radio Test Moves AMPG Shares

9 June 2026
AMPG soared 26.7% to $6.57 after AmpliTech revealed its 64T64R Massive MIMO radio was the only one of its kind at O-RAN PlugFest, showing interoperability with major carriers’ equipment, but no new orders were announced, leaving sales conversion as the key investor focus.
Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

Cartesian Growth Ticker Change Draws Trader Attention to Factorial Energy

9 June 2026
Factorial Energy surged 16% to $13.80 in its Nasdaq debut as FAC, with premarket trading near $20.70, after replacing CGCT via SPAC merger that raised over $100 million for battery commercialization and implied a $1.3 billion equity value; former CGCT shares now trade as FAC, with founders retaining majority voting power and staged lock-up releases ahead.
Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

Pfizer Falls in Premarket; Fresh FDA Approval Not Lifting the Stock

9 June 2026
Pfizer shares fell 1.7% premarket to $25.62 as investors weighed an FDA label expansion for hemophilia drug Hympavzi—now the first subcutaneous non-factor therapy for children 6-11 with hemophilia B—against slower progress in obesity drugs, with mid-stage data for weight-loss shot berobenatide showing a 23.3% vomiting rate and no immediate growth catalyst for the $147 billion company.
Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

Snap Shares Fall Even as Nasdaq Gains; June 16 in Focus

9 June 2026
Snap Inc. shares fell 1.9% to $5.65, underperforming a rising Nasdaq and leaving the stock 46% below its 52-week high, as investors weigh weak ad revenue growth, North American user declines, and cost-cutting moves against ongoing competitive pressure from Meta and TikTok.
Why Kweichow Moutai Co., Ltd. Class A stock (600519) is in focus: iMoutai restock and a fresh target cut
Previous Story

Why Kweichow Moutai Co., Ltd. Class A stock (600519) is in focus: iMoutai restock and a fresh target cut

BigBear.ai stock (BBAI) eyes Monday open after Kraft Group, Patriots tie-up; share vote looms
Next Story

BigBear.ai stock (BBAI) eyes Monday open after Kraft Group, Patriots tie-up; share vote looms

Go toTop